B-Type Natriuretic Peptide

Kandil, Emad; Burack, Joshua H.; Sawas, Ahmed; Bibawy, Haidy; Schwartzman, Alex E.; Zenilman, Michael E.; Bluth, Martin H.

doi:10.1001/archsurg.2007.69

Cited by 48 publications

(16 citation statements)

References 34 publications

(47 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…SubP gave higher specificity (83%) and sensitivity (80%) than NT-proBNP which was reported as an early marker candidate for the diagnosis of AMI patients in many groups. 10,21,27 From above results, we suggested SubP and NPY as early diagnostic biomarkers for AMI patients. The combination of two peptides analysis will give a chance to find for AMI patients in early stage.…”

Section: Resultsmentioning

confidence: 72%

“…21 Similar peptide markers, including atrial natriuretic peptide, B-type natriuretic peptide (BNP), and C-type natriuretic peptide have been studied extensively. 22 Currently, BNP, which is a peptide hormone released from cardiomyocytes upon a mechanical stretch, has been recommended for clinical use.…”

Section: Introductionmentioning

confidence: 99%

“…22 Currently, BNP, which is a peptide hormone released from cardiomyocytes upon a mechanical stretch, has been recommended for clinical use. 21,23 It is processed by furin and its inactive N-terminal (NT) fragment is NT-proBNP. 23 An NTproBNP of 8.5 kDa is now successfully used as a marker for congestive heart failure.…”

Section: Introductionmentioning

confidence: 99%

“…23 Indeed, recent studies have shown that assessment of the NT-proBNP concentration is useful in identifying cardiac disease. 21,25 Unfortunately, the area under the receiver operating characteristic (ROC) curve was below 70% and sensitivity and specificity values were below 80%. 26,27 Therefore, the development of a more sensitive and specific diagnostic biomarker is necessary for the early diagnosis of AMI.…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Substance P and Neuropeptide Y as Potential Biomarkers for Diagnosis of Acute Myocardial Infarction in Korean Patients

Han¹,

Seo²,

Jung³

et al. 2014

Bulletin of the Korean Chemical Society

View full text Add to dashboard Cite

Substance P and neuropeptide Y were discovered as early diagnostic biomarkers of acute myocardial infarction in Korean patients and confirmed using enzyme-linked immunosorbent assay (ELISA). We screened 12 peptides from the sera of Korean acute myocardial infarction (AMI) patients and detected 3 peptides (neuropeptide Y, substance P, and N-terminal pro-B-type natriuretic peptide) to be elevated from patients' sera by liquid chromatography mass/mass spectrometry. The elevated concentration of 3 peptides was confirmed by ELISA. The screening results revealed the substance P, neuropeptide Y, and pro-B-type natriuretic peptide (47-76) concentrations were higher in patients' sera than in healthy controls. The sensitivity and specificity of substance P for AMI diagnostic marker were 80% and 83%, respectively, and those of neuropeptide Y were 87% and 90%, respectively compared to healthy controls. These results suggest that substance P and neuropeptide Y could be used as early diagnostic biomarkers in patients with AMI.

show abstract

Section: Resultsmentioning

confidence: 72%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Substance P and Neuropeptide Y as Potential Biomarkers for Diagnosis of Acute Myocardial Infarction in Korean Patients

Han¹,

Seo²,

Jung³

et al. 2014

Bulletin of the Korean Chemical Society

View full text Add to dashboard Cite

show abstract

“…These median values were similar to those of the 51 patients in the study who had acute heart failure with BNP 581 pg/ml (6-1,300) and NT-proBNP 4,300 pg/ml (126-70,000). Kandil et al [66] also found that patients with septic shock on admission had significantly higher BNP levels compared to patients in early sepsis without a final diagnosis or a control group. Interestingly, BNP levels were not significantly elevated in patients with early sepsis.…”

Section: Elevated Nps In Other Disease Statesmentioning

confidence: 93%

Utility of natriuretic peptide testing in the evaluation and management of acute decompensated heart failure

Chiong

Jao

2009

Heart Fail Rev

View full text Add to dashboard Cite

The B-type natriuretic peptide (BNP) and the amino-terminal fragment of proBNP (NT-proBNP) are increased in heart failure in proportion to severity of symptoms, degree of left ventricular dysfunction, and elevation of cardiac filling pressures. These natriuretic peptides (NPs) are increasingly used for diagnostic and prognostic purposes in acute heart failure. While NP levels on admission provide independent prognostic information, serial determinations during hospitalization and at discharge better reflect adequacy of treatment and prognosis. The addition of BNP and NT-proBNP to usual clinical decision making enhances detection of high-risk patients who need aggressive follow-up and adjustment of treatment.

show abstract

Administration of Recombinant Activated Factor VII in Major Thoracic Operations

Alavi¹,

Jalali²,

Rasouli³

et al. 2008

Arch Surg

View full text Add to dashboard Cite

B-Type Natriuretic Peptide

Abstract: This study confirms the relationship between BNP level elevation and severity of sepsis independent of congestive heart failure. It also supports the utility of BNP level as a marker for mortality in septic shock.

Cited by 48 publications

References 34 publications

Substance P and Neuropeptide Y as Potential Biomarkers for Diagnosis of Acute Myocardial Infarction in Korean Patients

Substance P and Neuropeptide Y as Potential Biomarkers for Diagnosis of Acute Myocardial Infarction in Korean Patients

Utility of natriuretic peptide testing in the evaluation and management of acute decompensated heart failure

Administration of Recombinant Activated Factor VII in Major Thoracic Operations

Contact Info

Product

Resources

About